The number of nodules found in the thyroid is grown in the last decades, largely due to increasing neck examination by ultrasound scan. As a result, the number of fine-needle aspiration cytology (FNAC) procedures is also increased. Although FNAC is the most sensitive and accurate method for the differential diagnosis of thyroid nodules, about 20% of them yields indeterminate results [1] [2] [3] . This uncertainty leads to unnecessary diagnostic thyroid surgery that may result Abstract. Fine-needle aspiration cytology (FNAC) is the primary means to distinguish benign thyroid nodules from malignant ones. About 20% of FNAC yields indeterminate results leading to unnecessary or delayed surgery. Many studies of tissue samples, the majority of which are retrospective advocate testing for RET rearrangements as a diagnostic adjunctive tool in thyroid nodules with indeterminate cytological findings. Because of the uncertain prevalence of RET rearrangements, its utility as a tumor marker is still controversial. The goal of this study was to establish the prevalence and the utility of testing for RET rearrangements in FNAC suspicious of cancer in a clinical setting. In this prospective study, we analysed a large series of thyroid aspirates by RT-PCR only and Southern blot on RT-PCR products for type 1 and 3 RET rearrangements. Results were compared with clinical findings, cytological diagnosis and final histopathology. By the higher sensitive Southern-blot on RT-PCR method, RET rearrangements were present in 36% of papillary thyroid carcinomas (RET/PTC-1, 12%; RET/PTC-3, 20%; both, 4%) and of 13.3% of benign nodules. By means of RT-PCR only, RET rearrangements were disclosed only in 14.3% of PTC and in 3.6% of benign nodules. No significant correlation was found between RET rearrangements and clinicopathological features of patients. These results indicate that molecular testing of thyroid nodules for RET/PTC must take into account of its high prevalence in benign nodules, inducing false positive diagnoses when the highly sensitive assay Southern-blot on RT-PCR is used. Its searching by means of RT-PCR only, has a specificity superior of conventional cytology and can be used to refine inconclusive FNAC.
in additional morbidity and higher health care costs in patients with benign nodules, or in a delay in treatment or a limited surgery requiring a second operation to complete the thyroidectomy in patients with carcinoma. For this reason, several markers of malignancy have been investigated in the attempt to improve FNAC accuracy.
Some oncogenes with a demonstrated pathogenetic role in the thyroid cells transformation are among the most promising markers. The oncogene RET/PTC is involved in thyroid carcinogenesis and is associated with papillary thyroid carcinoma (PTC), the most frequent form of thyroid neoplasia. RET/PTC is a chimeric gene generated by the fusion of the tyrosine kinase domain of RET to the 5′ terminal region of yield a clear cytological diagnosis, were subjected to a second FNA procedure, performed twice consecutively in the same session after 3 weeks according to Baloch et al. [21] . One sample was used again for cytological examination and the other was dispersed into TRIreagent buffer (Sigma, St. Louis, MO) and stored at -20°C until RNA extraction. One hundred eightyfive patients were subjected to FNAC. Of these, 101 were subjected to thyroidectomy (3 with inadequate FNAC, 10 benign, 24 indeterminate, 19 suspicious for PTC and 45 malignant). The definitive diagnosis was benign in 30 nodules and malignant in 71 (50 PTC, 15 follicular (FTC), 1 undifferentiated (UTC) and 5 medullary (MTC) thyroid carcinomas). Tumors were staged according to the 6th edition of the TNM-based staging system, recommended by the American Joint Commission on Cancer (AJCC) and the International Union Against Cancer (UICC) [22] . Thyroid ultrasonography was performed using a 7.5-10 MHz linear transducer (Esaote, Genoa, Italy). The nodule volume was calculated according to the formula of the ellipsoid model: width × length × thickness × 0.52. The final histopathological findings were blindly reviewed by 5 independent pathologists.
RNA extraction and reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted using TRI-Reagent following the suggested protocol. The pellet of RNA was resuspended in 10 μL DEPC water and reverse transcribed with SuperScript III (Invitrogen, Milan, Italy) in a 20 μL reaction volume with random primers. The presence of thyroid follicular epithelial cells, the integrity of the RNA and the efficiency of the RT reaction in each sample was confirmed by PCR for thyroglobulin mRNA. The primers were chosen in such a way that the amplified fragments would include one splicing junction to avoid confusion with PCR products amplified from contaminating genomic DNA.
Detection of reT/PTC rearrangement: RT-PCR and Southern Blotting
Thyroglobulin, RET/PTC-1 and RET/PTC-3 were analyzed by RT-PCR using the previously reported primers [22] and oligoprobes specific for the TK domain, H4 or ELE1 (Table 1) . The annealing temperature was 56 C for RET/PTC-1 and 54 C for RET/ PTC-3. cDNA from WRO cells was used as negative control, while cDNA from TPC-1 cells and from a PTC genes that are constitutively expressed in thyroid follicular cells [4, 5] . The most frequent forms of this oncogene are RET/PTC-1 and RET/PTC-3, both arising from chromosome 10 inversions [6, 7] . The inappropriate expression of RET tyrosine kinase domain in the cytoplasm accounts for the oncogenic activity of the chimeric RET/ PTC gene. Its transforming activity has been demonstrated in the rat thyroid cells PCCl3 and in transgenic mice [8, 9] .
Searching for RET rearrangements in thyroid aspirates has already been reported as a useful tool in the preoperative diagnosis of PTC [10] [11] [12] [13] [14] [15] . However, to date there are two main concerns tempering the initial enthusiasm for its clinical application. One is the variability of the prevalence of RET/PTC rearrangements that in PTC is influenced by a number of factors, including geographic area, exposure to radiation, age of onset and methodology, and that varies widely in different studies from 0% to 92.3%. The second, and more important limit is that some studies have identified RET/PTC rearrangements in benign lesions including Hashimoto's thyroiditis and adenomas [16] [17] [18] [19] .
So far, most of the studies have been performed in tissue samples. In this study, we analysed a large series of thyroid aspirates for type 1 and 3 RET/PTC rearrangements, and the results were compared with the cytological diagnosis and final histopathology. RET rearrangements were searched by reverse transcription-polymerase chain reaction (RT-PCR) followed by ethidium bromide staining after electrophoresing on agarose gel, and Southern-blot on RT-PCR products and the results were compared.
Patients, materials and methods

Patients, ultrasonography, FNAC and histology
Patients from the Ospedale Mauriziano in the period 2006-2008 were entered in the study after obtaining their consent and with approval from the institutional review boards. Cytology samples of thyroid nodules were obtained using a 25-gauge needle passed three to four times. Smears were classified according to cytological classification from the British Thyroid Association and UK Royal College of Physicians and the Italian Society of Anatomic Pathology and Diagnostic Cytology (SIAPEC) Consensus: Thy 1, inadequate sample; Thy 2, benign; Thy 3 indeterminate or follicular lesions; Thy 4, suspicious and Thy 5, malignant [20] . Patients, whose FNAC results did not results Four-hundred consecutive patients were considered in the study. A few patients denied their consent or skipped the procedure. All Thy 1, 3, 4 and 5 (n= 12, 49, 33 and 45 respectively) were collected, along with 46 Thy 2 randomly selected. Only in one Thy 2 sample, thyroglobulin mRNA could not be detected and the search for the oncogenes was not performed. Of the 184 nodules analysed, 101 were removed by surgery and subjected to histopathological analysis, thus both cytology and definitive diagnosis were available. No subject was advised to surgery on the basis of a positive RET rearrangement. Table 2 reports the clinicopathological features of patients with a definitive histology diagnosis.
reT rearrangements by Southern blot on RT-PCR products
One hundred-one patients subjected to FNAC were also subjected to thyroidectomy because cytology disclosed a carcinoma (n=46), or was indeterminate (n=24), suspicious (n=19) or because of cosmetic or compressive symptoms (n=12). All samples were analyzed by means of the TK-probe, H4-probe and ELE-1-probe (Fig. 1) . Four nodules positive for RET/PTC were benign on histological analysis (13.3%) ( Table 3) . Nodules were bisected in the centre and then each half incised at intervals of 2-3 mm. Serial 6 µm thick sections were carefully evaluated for PTC microscopic foci of malignancy, that were not found. RET/PTC-1 and RET/PTC-3 were discovered in 6 and 10 PTC respectively, and in two more samples both rearrangements were found. Thus, RET rearrangements were present in 18/50 PTC (36.0%). No rearrangement was found in 15 FTC, 5 MTC and 1 UTC examined. No significant correlations were found between RET rearrangements and sex, age at diagnosis, tumor volume, presence of distant or lymph node metastasis and stage in sample were used as RET/PTC-1 and RET/PTC-3 positive controls respectively. Ten µL of PCR product was electrophoresed in 1.5% agarose gel and visualized by ethidium bromide. For Southern-blot, the PCR product was blotted onto a nylon membrane (Amersham Hybond N+, Amersham Place Little Chalfont, UK). Filters were then hybridized with two different internal probes specific for each amplified fragments, labelled with biotin, incubated with streptavidin-conjugated peroxidase and visualized using a chemiluminescent method (ECL Direct Nucleic Acid Labelling And Detection Systems Detection reagent, Amersham). Labeling, hybridization, and detection were performed according to the manufacturer's protocol. To control the specificity of the Southern blot in FNAC samples, the procedure was repeated using the cDNA extracted from randomly selected tissue samples, obtaining identical results. Furthermore, the PCR products of 4 samples positive for RET/PTC-1 (1 sample) or RET/PTC-3 (3 samples) were sequenced with the ET-terminators kit (Amersham) and run on the MegaBACE 500 (Amersham) capillary sequencer, demonstrating that the PCR amplified a chimeric cDNA containing H4 or ELE1 and the exon 12 of RET.
Statistical analysis
The results are analyzed as follows: sensitivity, truepositive/(true-positive + false-negative); specificity, true-negative/(true-negative + false-positive); accuracy, (true-positive + true-negative)/all samples examined; positive predictive value, true-positive/(truepositive + false-positive); negative predictive value, true-negative/(true-negative + false-negative). Results were also analyzed by means of the χ 2 of independence test with Prism (Version 3.00 for Windows; GraphPad Software, San Diego, CA, USA). The level of significance was set at <0.05. Since rearrangements of the RET proto-oncogene in PTC were discovered, they have been extensively studied by different methods in formalin-fixed and frozen tissues, and in cytology specimens. The claimed specificity of RET/PTC as a tumor marker raised the possibility for a clinical application in all those situations where the conventional cytology yields inconclusive results. As more studies were performed in different laboratories, it appeared that the incidence and the specificity of this oncogene as a tumor marker varied considerably, PTC, as well as age, sex and nodule volume in benign nodules (Table 4) .
Search for reT rearrangements by RT-PCR only and comparison with Southern-blot on RT-PCR products
To reduce the number of false positives, possibly due to the detection of few rearrangements in benign nodules, we compared RT-PCR and Southern-blot on RT-PCR products for RET/PTC-1 and RET/PTC-3 in 30 and 50 cytology samples from benign nodules and PTC respectively (Table 5) . In benign nodules, only 1 sample was positive for RET/PTC (RET/PTC-3, 3.3%) by means of RT-PCR. In PTC cytology specimens, only 8 (16.0%) resulted positive by RT-PCR. Based on these data, we compared the diagnostic value of RET/PTC and the cytology pattern of malignancy as a marker of PTC ( Table 6 ). As expected, the sensitivity of RT-PRC (18.7%) and Southern-blot (35.9%) was significantly lower than that of conventional cytology (94.0%) while only the specificity of RT-PCR (96.7%) was superior to that of cytology (86.7%). The performance of molecular testing was determined also in the Thy 1 (N=3), Thy 3 (N= 22) and Thy 4 (N= 19) FNAC. In the Thy1 and Thy 3 samples, no RET/PTC was disclosed, while in 2 samples of the Thy 4 group RET/ PTC was found by means of both methods.
Discussion
The main result of this study is the definition of the FTC 15 Total  101  101  7  13  2  22  22 PTC, papillary TC; FTC, follicular TC; UTC, undifferentiated TC; MTC, medullary TC lesion such as Hashimoto's thyroiditis, and to a lesser extent, in thyroid adenomas [16, 17, 19, 27] . While the presence of oncogenes in benign lesions might be involved in malignant conversion to thyroid carcinomas, its clinical implications is still a debated point.
Other genetic alterations such as Ras mutations and PAX8/PPARγ have been identified in some histopathologically classified benign nodules, suggesting that some benign thyroid nodules have a malignant potential or contain one or more microscopic foci of malignancy [28, 29] . In other cases, benignancy or malignancy cannot be assessed with certainty [30] . These lesions, if not malignant, should be considered as premalignant and subjected to surgery or to a careful follow-up. Although FISH appears to be more sensitive, we choose the Southern blot method on RT-PCR products to search for RET rearrangements because it is highly sensitive and easier to perform in cytology specimens.
In our study, a RET rearrangement was found in 13.3% (4/30) of histologically benign nodules by means of Southern blot on RT-PCR. In these nodules, careful microscopic observation did not disclose microscopic foci of malignancy. However, it cannot be excluded that sporadic scattered malignant cells escaped microscopic observation. Thus, to date nodules with Thy 2 cytology and RET rearrangements disclosed by means of Southern blot on RT-PCR must be considered benign in nature and should be treated with a conservative hampering its clinical application. The reported prevalence rates of RET/PTC varied largely among studies. While geographical factors and radiation exposure can partially account for this wide range of prevalence, the methodology applied appears to be the most important factor to explain this variability. In the early report by Corvi et al., the RET proto-oncogene was found rearranged in 52% of microcarcinomas by means of interphase fluorescence in situ hybridization (FISH) [23] . Unger et al. analysed tissues from post-Chernobyl papillary thyroid tumors by FISH, demonstrating that RET/ PTC rearrangements occurred only in a fraction of the cells, indicating that irradiated PTC were composed of a mixture of cells with and without RET rearrangement [24] . This study showed also a very high prevalence (72%) of recombinations as diagnosed by FISH interphase analysis. In the same study and in others, comparative analysis of FISH vs RT-PCR showed a higher frequency of recombinations by FISH, demonstrating that the sensitivity of the detection is a crucial factor affecting the prevalence of RET/PTC in thyroid tumors [25] . Zhu et al., compared the efficiency of RET/PTC detection by different methods in frozen tissues, confirming that the broad variability in the reported prevalence of RET/PTC rearrangement is the consequence of the different detection methods employed [26] . The application of highly sensitive techniques to search for RET rearrangements led also to the important observation that this genetic alteration can occur in benign RT-PCR, RT-PCR products visualized by ethidium bromide after electrophoresing on agarose gel; Southern, RT-PCR products blotted on nylon membrane and visualized by hybridization with specific oligoprobes. of genetic alterations reaching 100% of sensitivity for PTC. Such a panel, including RET/PTC and mutated BRaf and Ras, has been proposed to refine the diagnosis of FNAC of thyroid nodules [10, 15, 32] .
In conclusion, RET rearrangements are frequent in benign thyroid nodules. Because of its modest sensitivity, and low specificity, searching for RET/PTC by Southern-blot on RT-PCR is not advisable as a diagnostic tool. Detection of RET rearrangements by staining RT-PCR products by ethidium bromide after electrophoresing on agarose gel, can be used in cases with inconclusive cytology or in combination with other genetic alterations.
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This work has been supported in part by Ministero dell'Istruzione, dell'Università e della Ricerca (to M.V., and G.R.). We thank G.N. Burrow for critical reading of the manuscript and Dr. Juan Rosai for the review of histology samples. approach and a careful follow-up. The biological significance of RET/PTC transcripts at a very low level in benign nodules remains unclear. However, our preliminary observations suggest that the nodules bearing this oncogene might growth more rapidly [31] . If these data will be confirmed, molecular testing for RET rearrangements could have an impact on clinical management of benign thyroid nodules.
In our series of FNAC, the overall diagnostic performance of molecular testing for RET rearrangements was not superior to that of traditional cytology. RT-PCR not followed by Southern blot is a less sensitive method. However, searching for RET/PTC by RT-PCR alone had a specificity higher than that of cytology. Thus, it could have a clinical utility in those cases where cytology is unsuccessful (Thy 1 and Thy 3) or uncertain (Thy 4). In such cases, a negative molecular test would be meaningful, while a positive one should encourage the clinician to address the patient to surgery.
While it has a limited utility if used alone, searching for RET rearrangements may contribute to a panel references
